INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy

May 24, 2023

Biotechnology

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

April 26, 2024
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants

April 26, 2024
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

April 25, 2024
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

April 25, 2024